Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 27

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 27
---
 to revoke my proxy? |

| A: | Enfusion Stockholders of record may revoke their proxies at any time prior to the voting at the Special Meeting 
 in any of the following ways:                                                                                   |

| • |     | signing and delivering a new proxy relating to the same shares and bearing a later date than the original proxy; |

| • |     | sending a signed, written notice of revocation, which is dated later than the date of the proxy and states that                
 the proxy is revoked, to Enfusion, Inc., Attention: Legal Department, 125 South Clark Street, Suite 750, Chicago, IL 60603; or |

| • |     | participating in the Special Meeting and voting virtually. Participation in the Special Meeting will not, 
 however, in and of itself, constitute a vote or revocation of a prior proxy.                              |

Beneficial owners of shares held in “street name” may change their voting instructions only by following the directions received from their bank, brokerage firm or other nominee for changing their voting instructions.

| Q: | What happens if I sell my shares of Enfusion Common Stock before the Special Meeting? |

| A: | The record date is earlier than both the date of the Special Meeting and the Closing of the Transactions. If 
 you transfer your shares of Enfusion Common Stock after the record date but before the Special Meeting,      |

11

| you will, unless the transferee requests a proxy from you, retain your right to vote at the Special Meeting but will transfer the right to receive the Merger Consideration to the person to whom 
 you transfer your shares. In order to receive the Merger Consideration, you must hold your shares upon completion of the Transactions.                                                            |

| Q: | Do Enfusion Stockholders have appraisal rights? |

| A: | Yes. Enfusion Stockholders are entitled to appraisal rights under Section 262 of the Delaware General                                                                                                                            
 Corporation Law (the “DGCL”) in connection with the Merger provided they follow the procedures and satisfy the conditions set forth in Section 262 of the DGCL. For more information regarding appraisal rights, see the section 
 titled “Appraisal Rights of Enfusion Stockholders.” In addition, a copy of Section 262 of the DGCL is attached as Annex E to this Proxy Statement/Prospectus. Failure to strictly comply with Section 262 of the DGCL may        
 result in your waiver of, or inability to, exercise appraisal rights.                                                                                                                                                            |

| Q: | Who